Science Explorer Back to mapMap
Discussion
Company · Munich · Germany

Isarna Therapeutics (Germany)

isarna-therapeutics.comROR OpenAlex
Research works
16
▼ 81% vs 2018-21
Citations
135
8.4 per fractional work
Top-10% rate
25.6%
all institutions 10.0%
Open access
41%
world 40%
International
31%
world 18%
Isarna Therapeutics (Germany)

Not ranked overall: Isarna Therapeutics (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Isarna Therapeutics (Germany) work in?

In all years, 72% of research at Isarna Therapeutics (Germany) is in Life Sciences, 28% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (71%), Medicine (28%), Immunology and Microbiology (0%). It does 2.7× the world's share of Life Sciences.

Life Sciences: 12 fractional works · 72.0% of its workBiochemistry, Genetics and Molecular Biology: 12 fractional works · 71.5% of its workMolecular Biology: 9 fractional works · 54.0% of its workBiotechnology: 2 fractional works · 12.2% of its workCancer Research: 0 fractional works · 3.1% of its workGenetics: 0 fractional works · 1.6% of its workCell Biology: 0 fractional works · 0.5% of its workImmunology and Microbiology: 0 fractional works · 0.5% of its workImmunology: 0 fractional works · 0.5% of its workHealth Sciences: 4 fractional works · 27.6% of its workMedicine: 4 fractional works · 27.6% of its workOncology: 2 fractional works · 10.0% of its workOphthalmology: 1 fractional works · 5.2% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 3.5% of its workHepatology: 0 fractional works · 2.8% of its workGenetics: 0 fractional works · 2.0% of its workSurgery: 0 fractional works · 1.9% of its workImmunology and Allergy: 0 fractional works · 1.2% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.7% of its workEpidemiology: 0 fractional works · 0.2% of its workPhysical Sciences: 0 fractional works · 0.2% of its workEnvironmental Science: 0 fractional works · 0.2% of its workEcology: 0 fractional works · 0.2% of its workSocial Sciences: 0 fractional works · 0.1% of its workSocial Sciences: 0 fractional works · 0.1% of its workALL ITS WORKIsarnaTherapeutics…16fractional works, all years
Life Sciences72%Physical Sciences0%Health Sciences28%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 5 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology1271.5%
    2. Immunology and Microbiology00.5%
    1. Medicine427.6%
    1. Environmental Science00.2%
    1. Social Sciences00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Who are the top researchers at Isarna Therapeutics (Germany)?

Ranked on the quality score, Michel Janicot, Hanna Korhonen and Michel Janicot lead among researchers whose main affiliation is Isarna Therapeutics (Germany).

  1. 1 Michel Janicot Germany · #1,178,538 worldwide 2.3k citations · 126 works
  2. 2 Hanna Korhonen Germany · #1,305,489 worldwide 783 citations · 29 works
  3. 3 Michel Janicot Germany · #3,216,742 worldwide 824 citations · 34 works
  4. 4 Katja Wosikowski Germany · #3,593,325 worldwide 1.2k citations · 45 works
All ranked researchers at Isarna Therapeutics (Germany)

What are the most cited papers from Isarna Therapeutics (Germany)?

The most cited paper from Isarna Therapeutics (Germany) is "First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery" (Norbert Pfeiffer, Bogomil Voykov, Giulia Renieri et al., 2017), with 69 citations. Next come "TGF-β1 and TGF-β2 abundance in liver diseases of mice and men" (62) and "Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma" (60).

Most cited papers
#PaperReleasedCitations
1 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery Norbert Pfeiffer, Bogomil Voykov, Giulia Renieri et al. · PLoS ONE Open access 30 Nov 2017 69
2 TGF-β1 and TGF-β2 abundance in liver diseases of mice and men Anne Dropmann, Tatjana Dediulia, Katja Breitkopf‐Heinlein et al. · Oncotarget Open access 21 Jan 2016 62
3 Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma Katharina Seystahl, Alexandros Papachristodoulou, Isabel Burghardt et al. · Molecular Cancer Therapeutics Open access 4 Apr 2017 60
4 Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas Alexandros Papachristodoulou, Manuela Silginer, Michael Weller et al. · Clinical Cancer Research Open access 17 Sep 2019 51
5 TGF-β2 silencing to target biliary-derived liver diseases Anne Dropmann et al. · Gut Open access 28 Jan 2020 43
All 22 most cited papers, with filters and sorting

Which research topics does Isarna Therapeutics (Germany) publish most on?

By volume in 2022-now: Virus-based gene therapy research, Liver physiology and pathology, Acute Lymphoblastic Leukemia research and RNA and protein synthesis mechanisms.

  1. 1 Virus-based gene therapy research Genetics 0 works
  2. 2 Liver physiology and pathology Hepatology 0 works
  3. 3 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 0 works
  4. 4 RNA and protein synthesis mechanisms Molecular Biology 0 works
  5. 5 Bacteriophages and microbial interactions Ecology 0 works
  6. 6 RNA Research and Splicing Molecular Biology 0 works
  7. 7 Viral-associated cancers and disorders Oncology 0 works
  8. 8 Bladder and Urothelial Cancer Treatments Surgery 0 works
  9. 9 Diabetes and associated disorders Genetics 0 works
  10. 10 Liver Diseases and Immunity Hepatology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available40.6%not open59.4%

World: 40% of research is openly available.

with international co-authors30.6%domestic only69.4%

World: 18% is written across borders.

How has Isarna Therapeutics (Germany)'s research output changed?

Output in 2022-2025 was 81% lower than in 2018-2021.

still counting2010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Isarna Therapeutics (Germany) as a percentage of every work published that year, 0.0000013% in 2023.

still counting0.000050%0.00010%0.00015%Isarna Therapeutics (Germany)0.0000061% in 202520102020

Fractional works of Isarna Therapeutics (Germany) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Munich

All research institutions in Munich

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Isarna Therapeutics (Germany). Posts are plain text and can be reported.